Results 131 to 140 of about 26,835 (181)

Melanoma/CSPG4-Enhanced Collagen-Mediated Contact Guidance Requires Mutant Active BRAF and the CSPG4 Core Protein Cytoplasmic Domain. [PDF]

Cell Mol Bioeng
Thrivikraman G, Yang J, Price M, Giubellino A, McCarthy JB, Tranquillo RT.   +5 more
europepmc   +1 more source

Development of a biomimetic thyroid acellular scaffold as a 3D platform for modeling thyroid cancer aggressiveness and drug resistance. [PDF]

Front Bioeng Biotechnol
Zhang L, Sun R, Li S, Zhang P, Long H, Liu B, Li F.   +6 more
europepmc   +1 more source

Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment. [PDF]

NPJ Precis Oncol
Lu K, Shen JP, Lopez-Diaz FJ, Leal A, Mambetsariev I, Parikh K, Hazim A, Woodward BD, Madduri A, Khurshid F, Fricke J, Velcheti V, Riess JW, Mansfield AS, Salgia R, Husain H.   +15 more
europepmc   +1 more source

Suppression of Sebum Production by Vemurafenib Through Paradoxical ERK Activation Resulted in the Inhibition of the mTOR Pathway in 5α-Dihydrotestosterone-Differentiated Hamster Sebocytes In Vitro. [PDF]

Exp Dermatol
Koiwai T, Sato T.
europepmc   +1 more source

Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug Testing. [PDF]

ACS Appl Bio Mater
Vázquez-Aristizabal P, Arriola-Alvarez I, Henriksen-Lacey M, Alonso-Martin S, van den Broek L, Liz-Marzán LM, Izeta A.   +6 more
europepmc   +1 more source

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Belloni S, Virgili R, Caruso R, Arrigoni C, Magon A, Rocco G, De Maria M.   +6 more
europepmc   +1 more source

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer. [PDF]

J Transl Med
Wei GX, Zhou YW, Cao P, Leng WB, Wang L, Tang J, Qiu M.   +6 more
europepmc   +1 more source

Erdheim-Chester Disease: A Diagnostic Challenge. [PDF]

Cureus
Soares Costa T, Noversa de Sousa R, Oliveira M, Calisto R, Rocha D, Pereira PR.   +5 more
europepmc   +1 more source

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy. [PDF]

Cancer Med
Rapisuwon S, Slingluff CL, Wargo JA, Sullivan RJ, Izar B, Lin JR, Mauldin IS, Olson WC, Tran CA, Schwartzman GH, Gibney GT, Al-Refaie W, Atkins MB.   +12 more
europepmc   +1 more source

TMTP1-Modified Small Extracellular Vesicles Target BRAF Mutation in Anaplastic Thyroid Cancer Reversing Vemurafenib Resistance With CRISPR/Cas9 Delivery. [PDF]

J Extracell Vesicles
Zhang S, Ji Z, Cheng X, Ma Y, Feng M, Cai D, Bai T.   +6 more
europepmc   +1 more source